Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In API Battle, China Chips Away At India’s Share; India Calls For Policy Safeguards

This article was originally published in PharmAsia News

Executive Summary

China is becoming a serious threat to India’s indigenous API manufacturers, as India seeks policy safeguards such as anti-dumping duties and stricter inspections on Chinese imports.

You may also be interested in...



India Should Play Up R&D Strengths But Build "China-like" Infrastructure - BIO India Conference

HYDERABAD - Indian companies are more entrepreneurially driven than their Chinese counterparts, and although a noticeable switch in mindset toward innovation is welcomed, the government needs to participate more in building infrastructure to raise confidence levels for global companies to funnel more research work to India, multinational companies urged

India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle

MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck

Competition To Cooperation: Indian And Chinese Firms Agree On Draft MOU For Partnerships, Investments And GMP Training

MUMBAI - Intense price competition in key developed markets and common concerns for quality products and GMP issues is set to bring India and China together to boost collaborative efforts

Topics

UsernamePublicRestriction

Register

SC079453

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel